Halberd's patent position insured high potential of technical and market success. Halberd chose neurodegenerative diseases as its primary focus, since there are approximately 36 million people ...
Halberd demonstrated elimination of the final two of the "Top Ten" antigens linked to neurodegenerative diseases. Halberd demonstrated that its antigen elimination process is able to selectively ...
Mississippi State University (MSU) is well on their way in testing Halberd's patent-pending nasal spray to mitigate the neurological effects resulting from traumatic brain injuries (TBI). By directly ...
JACKSON CENTER, PA / ACCESSWIRE / September 27, 2022 / Halberd Corporation (OTC PINK:HALB) entered into a strategic alliance with AI Longevity, Inc. and Stem of Hope to form a strategic alliance as a ...
JACKSON CENTER, PA / ACCESSWIRE / October 18, 2022 / Halberd Corporation (OTC PINK:HALB) has successfully eliminated various antibiotic resistant bacteria from buffer solution in-vitro through the use ...
Halberd management has guided the company thus far to achieve technological advancements beyond those of Big Pharma. Halberd's success was demonstrated by way of publication of the peer-reviewed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results